SCIENCE AT THE SPEED OF BUSINESS

Our fundamental premise is that innovative methods, analytical rigor, and scientific acumen can be provided in a commercial entity that operates “at the speed of business.” Monument Analytics delivers.

Unparalleled Knowledge Base

One of the most remarkable features of Monument Analytics is its access to consultants with an unparalleled knowledge base. Through its independent consulting services, Monument Analytics leverages this acumen to assist clients developing products and services for the benefit of society.

Top Notch Evidence

By capitalizing on this unparalleled depth and breadth of human capital, Monument Analytics is able to generate the highest quality evidence regarding the safety, effectiveness, and real-world value of the full range of medical processes and technologies; and to use this knowledge to help our clients navigate evermore complex and challenging regulatory and payment environments.

Internationally Renowned Experts

Our Principals and Consultants are internationally renowned for their expertise in areas ranging from epidemiology and biostatistics to clinical fields such as cardiovascular medicine, oncology, and immunology.

G. Caleb Alexander
G. Caleb AlexanderMD, MS
CO-FOUNDER & PRINCIPAL
Jonothan C. Tierce
Jonothan C. TierceCPhil
CO-FOUNDER & PRINCIPAL
William V. Padula
William V. PadulaPhD
PRINCIPAL
Natalie Reid
Natalie ReidPhD, MPH, MBA
DIRECTOR
MEET THE CONSULTING TEAM

Services

Our services are broadly organized into four core capabilities

  • Comparative effectiveness analyses
  • Pharmacovigilance and safety assessments
  • Investigations of drug utilization
  • Risk-benefit appraisals
  • Bayesian, meta-analytic and systematic reviews
  • Patient and clinician preferences
  • Global marketplace and pharmaceutical policy
  • Design and conduct of sophisticated comparative effectiveness, pharmacovigilance, and drug utilization studies
  • Advanced techniques for causal inference, management of missing data, and other statistical analysis
  • Cost-benefit analysis and cost-effectiveness analysis
  • Natural history of disease and resource utilization
  • Systematic economic and quality-of-life reviews
  • Core value dossiers

MA in the News

March 12, 2021
Bill Padula

Monument Analytics Principal Dr. Bill Padula was quoted in The Marin Independent Journal article titled: “COVID vaccines: Will California meet Biden’s May 1 goal?” Dr. Padula shared his views regarding logistics of vaccine distribution in California.

March 10, 2021
Bill Padula

Monument Analytics Principal Dr. Bill Padula was quoted in The Marin Independent Journal article titled: “Tensions mount over California’s vaccine distribution plan.” Dr. Padula shared his views regarding public and private vaccine distribution in California.

March 9, 2021
Bill Padula

Monument Analytics Principal Dr. Bill Padula was quoted in The Mercury News article titled: “COVID: Will revolt over Blue Shield cost Santa Clara County access to vaccine?” Dr. Padula shared his views regarding public and private partnerships for vaccine distribution.

March 5, 2021
Caleb Alexander

Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was quoted in an article in Law360 titled: “Opioid Litigation Is Prying Open Vaults Of Big Pharma Secrets.” The article discussed ongoing opioid litigation and parallels to tobacco litigation.

February 23, 2021
Monument Analytics: Bill Padula, Natalie Reid, Jon Tierce

Monument Analytics team members co-authored a Value & Outcomes Spotlight titled: “Health Technology Assessment for COVID-19 Treatments and Vaccines: Will Cost-Effectiveness Analysis Serve Our Needs?

February 19, 2021
Caleb Alexander

Monument Analytics Co-Founder and Principal Dr. Caleb Alexander was interviewed by Healio Rheumatology about his publication in Clinical Infectious Diseases titled: “Association Between Chronic Use of Immunosuppressive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System.” This research study showed that individuals taking chronic immunosuppressive medications do not fare worse in terms of COVID outcomes.

SEE ALL NEWS